Met kinase inhibitors

Details Met kinase inhibitors Met kinase inhibitors

2006-09-13

2010-06-08

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S153000

Reexamination Certificate

active

07732613

ABSTRACT:
The present invention is directed to compounds that are useful for treating cancer having one of the following Formulas:

REFERENCES:
patent: 6214344 (2001-04-01), Schwall et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6828320 (2004-12-01), Cockerill et al.
patent: 6858626 (2005-02-01), Xue et al.
patent: 2005/0288290 (2005-12-01), Borzilleri et al.
patent: 2006/0004006 (2006-01-01), Borzilleri et al.
patent: WO01/21594 (2001-03-01), None
patent: WO01/21596 (2001-03-01), None
patent: WO01/77085 (2001-10-01), None
patent: WO2004/018430 (2004-03-01), None
patent: WO2005/030140 (2005-04-01), None
Bardelli, A. et al., “Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required forMET-mediated metastasis”, Oncogene, vol. 18, pp. 1139-1146 (1999).
Bottaro, D. et al., “Identification of the Hepatocyte Growth Factor Receptor as the c-metProto-Oncogene Product”, Science, vol. 251, pp. 802-804 (1991).
Bussolino, F. et al., “Hepatocyte Growth Factor is a Potent Angiogenic Factor which Stimulates Endothelial Cell Motility and Growth”, The J. of Cell Biology, vol. 119(3), pp. 629-641 (1992).
Camp, R. et al., “MetExpression is Associated with Poor Outcome in Patients with Axillary Lymph Node Negative Breast Carcinoma”, Cancer, vol. 86(11), pp. 2259-2265 (1999).
Cañibano, V. et al., “Mild Regioselective Halogenation of Activated Pyridines withN-Bromosuccinimide”, Synthesis, vol. 14, pp. 2175-2179 (2001).
Christensen, J. et al., “A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo”, Cancer Research, vol. 63, pp. 7345-7355 (2003).
Cooper, C. et al., “Amplification and overexpression of themetgene in spontaneously transformed NIH3T3 mouse fibroblasts”, The EMBO Journal, vol. 5(10), pp. 2623-2628 (1986).
Di Renzo, M. et al., “Overexpression and Amplification of the Met/HGF Receptor Gene during the Progression of Colorectal Cancer”, Clinical Cancer Research, vol. 1, pp. 147-154 (1995).
Furge, K. et al., “Met receptor tyrosine kinase: enhanced signaling through adapter proteins”, Oncogene, vol. 19, pp. 5582-5589 (2000).
Gual, P. et al., “Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis”, Oncogene, vol. 19, pp. 1509-1518 (2000).
Jiang, W. et al., “Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET”, Clinical Cancer Research, vol. 9, pp. 4274-4281 (2003).
Kenworthy, P. et al., “The presence of scatter factor in patients with metastatic spread to the pleura”, Br. J. Cancer, vol. 66, pp. 243-247 (1992).
Kubo, K. et al., “Novel Potent Orally Active Selective VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Structure-Activity Relationships, and Antitumor Activities ofN-Phenyl-N′-{4-(4-quinolyloxy) phenyl} ureas”, J. Med. Chem., vol. 48, pp. 1359-1366 (2005).
Lai, J. et al., “Involvement of Focal Adhesion Kinase in Hepatocyte Growth Factor-induced Scatter of Madin-Darby Canine Kidney Cells”, The J. of Biological Chemistry, vol. 275(11), pp. 7474-7480 (2000).
Lee, J. et al., “A novel germ line juxtamembraneMetmutation in human gastric cancer”, Oncogene, vol. 19, pp. 4947-4953 (2000).
Lubensky, I. et al., “Hereditary and Sporadic Papillary Renal Carcinomas with c-metMutations Share a Distinct Morphological Phenotype”, American J. of Pathology, vol. 155(2), pp. 517-526 (1999).
Masuya, D. et al., “The tumor-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients”, British J. of Cancer, vol. 90, pp. 1555-1562 (2004).
Matsumoto, K. et al., “Hepatocyte Growth Factor: Molecular Structure, Roles in Liver Regeneration, and Other Biological Functions”, Critical Reviews in Oncogenesis, vol. 3(1,2), pp. 27-54 (1992).
Montesano, R, et al., “Identification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor”, Cell, vol. 67, pp. 901-908 (1991).
Park, M. et al., “Sequence ofMETprotooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors”, PNAS, vol. 84, pp. 6379-6383 (1987).
Rong, S. et al., “Met Expression and Sarcoma Tumorigenicity”, Cancer Research, vol. 53, pp. 5355-5360 (1993).
Rong, S. et al., “Met Proto-oncogene Product Is Overexpressed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients”, Cancer Research, vol. 55, pp. 1963-1970 (1995).
Sachs, M. et al., “Essential Role of Gab1 for Signaling by the c-Met Receptor In Vivo”, The J. of Cell Biology, vol. 150, pp. 1375-1384 (2000).
Scarpino, S. et al., “Hepatocyte Growth Factor (HGF) Stimulates Tumour Invasiveness in Papillary Carcinoma of the Thyroid”, J. of Pathology, vol. 189, pp. 570-575 (1999).
Schaeper, U. et al., “Coupling of Gab1 to c-Met, Grb2, and Shp2 Mediates Biological Responses”, The J. of Cell Biology, vol. 149, pp. 1419-1432 (2000).
Soman, N. et al., “TheTPR-METoncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions”, PNAS, vol. 88, pp. 4892-4896 (1991).
Sonnenberg, E. et al., “Scatter Factor/Hepatocyte Growth Factor and Its Receptor, the c-met Tyrosine Kinase, Can Mediate a Signal Exchange between Mesenchyme and Epithelia during Mouse Development”, The J. of Cell Biology, vol. 123, pp. 223-235 (1993).
Stabile, L. et al., “Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy”, Gene Therapy, vol. 11, pp. 325-335 (2004).
Stella, M. et al., “HGF: a multifunctional growth factor controlling cell scattering”, The International J. of Biochemistry & Cell Biology, vol. 31, pp. 1357-1362 (1999).
Stoker, M. et al., “Scatter factor is a fibroblast-derived modulator of epithelial cell mobility”, Nature, vol. 327, pp. 239-242 (1987).
Stuart, K. et al., “Hepatocyte growth factor/scatter factor-induced intracellular signaling”, International J. of Experimental Pathology, vol. 81, pp. 17-30 (2000).
Takayama, H. et al., “Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor”, PNAS, vol. 94, pp. 701-706 (1997).
Tanimura, S. et al., “Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering”, Oncogene, vol. 17, pp. 57-65 (1998).
Kubo et al.,Synthesis and Structure-Activity Relationship for New Series of 4-Phenoxyquinoline Derivatives as Specific Inhibitors of Platelet-Derived growth Factor Receptor Tyrosine Kinase, Bio. Med. Chem., vol. 11, Aug. 2003, pp. 5117-5133.
Tsou et al.,Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreverible Inhibitors of HEGFR-2 Kinase Activity, J. Med. Chem., vol. 48, Jan. 27, 2005, pp. 1107-1131.

Affiliated with

Also associated with

Rating

Met kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Met kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Met kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4242925